BeiGene Trial of Lung-Cancer Treatment Reaches Primary Endpoints
By Ben Glickman
BeiGene's trial of the use of tislelizumab to treat resectable non-small cell lung cancer, when combined with chemotherapy, reached its dual primary endpoints.
The biotechnology company said on Tuesday that its Phase 3 trial met endpoints for major pathological response and event-free survival. The trial found statistically significant and clinically meaningful improvements in resectable NSCLC patients when treated with tislelizumab and chemotherapy before surgery, then as a single agent post-surgery.
The trial also showed a statistically significant improvement in pathological complete response, a key secondary endpoint.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 17, 2023 16:25 ET (20:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom